KRAS and non-small cell lung carcinoma: Although previous studies showed that pharmacological inhibition of TBK1 results in feedback ERK activation, a phase I clinical trial investigating the treatment of JAK1/JAK2 inhibitor momelotinib and trametinib in metastatic KRAS-mutant NSCLC patients who have failed chemotherapy provided no improved activity over single-agent trametinib at the doses used (ClinicalTrials.gov identifier: NCT02258607)93.